SCHEMBL6913478

SCHEMBL6913478

CC(C)(C)OC(=O)N1CC(Cc2nc(-c3ccc(F)cc3)cs2)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
ENPP2 Q13822 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
GALR3 O60755 1/20 0.44
USP30 Q70CQ3 2/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22462811 0.86 L3MBTL1 (0.56) L3MBTL1NPC1RAB9ACASP3SENP8
SCHEMBL2227569 0.83 RAB9A (0.48) L3MBTL1NPC1RAB9ACASP3SENP8
SCHEMBL17296109 0.77 NAMPT (0.48) LMNAHDAC1HDAC2
SCHEMBL3767361 0.76 ENPP2 (0.57) ENPP2SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL6913568 0.76 TRPV1 (0.52) L3MBTL1NPC1RAB9ACASP3SENP8
SCHEMBL3767565 0.75 MAPT (0.74) L3MBTL1NPC1RAB9AENPP2SMN1; SMN2
SCHEMBL6913121 0.74 SMN1; SMN2 (0.44) L3MBTL1NPC1RAB9ACASP3SENP8
SCHEMBL634516 0.73 PIK3CD (0.46) MAPTUSP30
SCHEMBL31336160 0.71 SMN1; SMN2 (0.47) L3MBTL1NPC1RAB9ACASP3SENP8
SCHEMBL29764173 0.71 SMN1; SMN2 (0.47) L3MBTL1NPC1RAB9ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
WO-2011088192-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B L3MBTL1 1054/4885NPC1 825/4885RAB9A 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.